News and updates

Current press releases, talks and reports

NEO New Oncology AG Closes Financing Round

Cologne, October 9, 2015 – NEO New Oncology AG, a Cologne based cancer diagnostics company, today announced the closing of a financing round with a total investment of app. EUR 5 Million.

“I am pleased by the strong interest that NEO New Oncology AG has received from the investment community,” commented Dr. Andreas Jenne, CEO of NEO New Oncology AG. “Together with the proceeds from the first closing earlier this year, the funds will help us to make NEOliquid, a genomic diagnostics test that identifies all therapeutically actionable genome alterations from a simple blood sample, available to patients even faster.”

About NEO New Oncology AG
NEO New Oncology AG’s proprietary pan-cancer diagnostic platform ‘NEO’ empowers physicians to select the optimal targeted therapy for their patients, including participation in suitable clinical trials. NEO reliably detects actionable genetic alterations with short turn-around times in routine clinical specimens such as paraffin embedded tissue, cytology or blood. In contrast to conventional testing, NEO identifies all types of therapeutically relevant alterations, i.e. point mutations, amplifications, insertions/deletions, as well as novel and selected known translocations, from one single patient sample. NEO New Oncology AG works with a tumor board of renowned cancer experts, facilitating translation of the latest targeted therapy findings into optimized patient care.

Dr. Jutta Fritz
NEO New Oncology AG

Presse release
#04 2015

to download